Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertension

Trial Profile

Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Amlodipine/azilsartan (Primary) ; Amlodipine; Azilsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 14 Apr 2014 Results published in the Clinical Therapeutics.
    • 24 Mar 2014 Based on results from this and another phase III trial, NDA was approved in Japan for low dose and high dose combination tablets of amlodipine/azilsartan [Zacras], according to a Takeda media release.
    • 02 May 2013 New source identified and integrated: Japan Pharmaceutical Information Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top